RVMD Revolution Medicines Inc - Ordinary Shares

Biotech Analyst Ratings

Latest News

1. 09 May 2022 Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

   Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RAS^MULTI) and RMC-6291 (KRAS^G12C) approaching the clinic

   RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination with Lumakras™ (sotorasib) in patients with advanced non-small cell lung cancer continues enrolling

   RMC-5552 (mTORC1) has exhibited preliminary evidence of clinical activity, and dose optimization is underway to prepare for combination studies in RAS cancers

   Conference call and webcast today at 4:30 p.m. Eastern Time

   REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for…

   View Full Article
2. 21 April 2022 Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

   REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.
   

   Conference Call and Webcast Information:

   • Dial-in: (833) 423-0425 (U.S.) or + 1 (918) 922-3069 (international); conference ID 6994747.
   • Live webcast with slides can be accessed at: https://ir.revmed.com/events-and-presentations…

   View Full Article
3. 09 March 2022 Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

   REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.
   

   Four of the company's oral presentations will be featured in the conference mini-symposium session entitled "Targeting the RAS Oncogene." These presentations will describe recent research findings regarding Revolution Medicines' broad pipeline of RAS(ON) Inhibitors currently in development, including RMC-6236 (RAS^MULTI), RMC-6291 (KRAS^G12C), RMC-9805 (KRAS…

   View Full Article
4. 01 March 2022 Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

   REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42^nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.
   

   Details of the company's participation are as follows:

   • Cowen 42^nd Annual Health Care Conference
     Conference Date: March 7-9, 2022
     Fireside Chat Time/Date: 11:10 a.m. Pacific on Monday, March 7, 2022
     Format: Virtual conference; webcast available

   To access the live webcast of the fireside chat, please…

   View Full Article
5. 28 February 2022 Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

   RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated
   

   Recently Announced First Patient Dosed in Global Phase 2 Study Evaluating Combination of RMC-4630 and Lumakras™ (sotorasib) in Patients with Advanced Non-Small Cell Lung Cancer

   mTORC1-Selective Inhibitor, RMC-5552, Demonstrates Preliminary Evidence of Clinical Activity in Ongoing Phase 1/1b Monotherapy Study

   REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced its financial results for the fourth quarter and year ended December 31, 2021…

   View Full Article